These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 3904908

  • 1. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine.
    Bishop MC, Selby C, Taylor M.
    Br J Urol; 1985 Oct; 57(5):542-7. PubMed ID: 3904908
    [Abstract] [Full Text] [Related]

  • 2. Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate.
    Morales A, Nickel JC.
    Urology; 1985 Nov; 26(5):477-81. PubMed ID: 3904134
    [Abstract] [Full Text] [Related]

  • 3. Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate.
    Fosså SD, Fosså J, Aakvaag A.
    J Urol; 1977 Dec; 118(6):1013-8. PubMed ID: 926240
    [Abstract] [Full Text] [Related]

  • 4. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP, Wajsman Z, Kirdani RY, Murphy GP, Sandberg AA.
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [Abstract] [Full Text] [Related]

  • 5. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ, Morales A.
    Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
    [Abstract] [Full Text] [Related]

  • 6. Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol.
    Daponte D, Sylvester R, De Pauw M, Fryszman A, Smith RM, Smith PH.
    Br J Urol; 1983 Aug; 55(4):408-12. PubMed ID: 6349745
    [Abstract] [Full Text] [Related]

  • 7. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
    Hauchecorne J.
    Prog Clin Biol Res; 1987 Aug; 243B():229-34. PubMed ID: 3309983
    [No Abstract] [Full Text] [Related]

  • 8. The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin.
    Daehlin L, Damber JE, von Schoultz B, Bergman B.
    Br J Urol; 1986 Aug; 58(4):412-6. PubMed ID: 3092893
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
    Benson RC, Gill GM, Cummings KB.
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
    [No Abstract] [Full Text] [Related]

  • 11. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
    Smith PH, Suciu S, Robinson MR, Richards B, Bastable JR, Glashan RW, Bouffioux C, Lardennois B, Williams RE, de Pauw M.
    J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
    [Abstract] [Full Text] [Related]

  • 12. [Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].
    Daponte DP, Stevens I, Robinson MR.
    Actas Urol Esp; 1986 Sep; 10(6):437-40. PubMed ID: 3825644
    [No Abstract] [Full Text] [Related]

  • 13. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
    Benson RC, Cummings K.
    Prog Clin Biol Res; 1989 Sep; 303():177-86. PubMed ID: 2674984
    [No Abstract] [Full Text] [Related]

  • 14. Plasma prolactin, GH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens.
    Boyns AR, Cole EN, Phillips ME, Hillier SG, Cameron EH, Griffiths K, Shahmanesh M, Feneley RC, Hartog M.
    Eur J Cancer (1965); 1974 Jul; 10(7):445-9. PubMed ID: 4376085
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prostatic cancer. Transcortin levels during treatment with estramustine phosphate.
    Sandberg AA, Rosenthal H, Mittelman A, Murphy GP.
    Urology; 1975 Jul; 6(1):17-21. PubMed ID: 1145919
    [Abstract] [Full Text] [Related]

  • 18. Hormonal effects of different doses of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
    Fritjofsson A, Norlén BJ, Högberg B, Rajalakshmi M, Cekan SZ, Diczfalusy E.
    Scand J Urol Nephrol; 1981 Jul; 15(1):37-44. PubMed ID: 6787701
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.
    Smith PH, Robinson M, Richards B, Suciu S, De Pauw M, Sylvester R, Denis L.
    Urology; 1984 Jun; 23(6 Suppl):64-8. PubMed ID: 6375083
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.